Stephen W. Gilheeney, MD, MMS

About Me

I am a pediatric oncologist who specializes in treating children and young adults with brain and spinal tumors. I am a member of a dedicated and compassionate multidisciplinary team of pediatric specialists at Memorial Sloan Kettering that includes radiation oncologists, neurosurgeons, neuroradiologists, and neurologists.

Read more

In my research, I am developing treatment strategies to effectively target cancer cells and that have minimal side effects. I collaborate with my colleagues here at Memorial Sloan Kettering and with researchers at other centers across the United States, as well as industry partners, to develop new treatments.

I am a member of the Pediatric Brain Tumor Consortium (PBTC). This group comprises researchers at several American cancer centers who collaborate to conduct phase I and II studies of new therapies. My current research focus is developing and assessing targeted therapies, small molecule inhibitors, and combination therapies for a range of tumor types.

I am the Associate Director of the Pediatric Neuro-Oncology Fellowship program at Memorial Sloan Kettering, and I am very active in educating doctors who are training in pediatrics, pediatric oncology, and pediatric neuro-oncology. I am a reviewer for several medical journals, including the Journal of Pediatric Hematology/Oncology and Pediatric Blood Cancer. Nationally, I serve on the Children’s Oncology Group Diffuse Pontine Glioma Committee.

When I started working in neuro-oncology, I had chosen this field because I loved the science. But now I love working with the children even more. Their positive attitude makes my career very rewarding.

See My Colleagues

Publications

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Clinical Trials

Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.